Celecoxib (Celebrex) Pathway     under review

    Representation of the candidate genes involved in the metabolism of celecoxib and its mechanism of action.  
Legend  
© 2010 PharmGKB
DESCRIPTION:  Celecoxib (Celebrex) is a selective cycloxygenase-2 (PTGS2/ COX-2) inhibitor used for treatment of osteoarthritis and rheumatoid arthritis. It acts by reducing prostaglandin synthesis through inhibition of COX-2. Selective COX-2 inhibitors appear to provide comparable anti-inflammatory effects to conventional non-steroidal anti-inflammatory agents (NSAIDs), while avoiding serious adverse reactions, in particular, gastrointestinal toxicity observed with chronic use of NSAIDs due to COX-1(PTGS1) inhibition.

PK: Celecoxib is rapidly absorbed and achieves peak serum concentration in about 3 hours after an oral dose. It is metabolized primarily in liver by CYP2C9 into carboxylic acid and glucuronide metabolites in humans, although CYP3A4 also plays a minor role (PMID:10681375). Polymorphisms in CYP2C9 have a direct impact on celecoxib pharmacokinetics and variability in drug responses. People that are poor metabolizers of CYP2C9 substrates (eg. CYP2C9*3 allele carriers) will have greatly increased exposure to celecoxib (PMID:12893985). Drugs that inhibit CYP2C9 should also be used with caution in patients taking celecoxib due to the fact that CYP2C9 is its major route of metabolism. Celecoxib is an inhibitor of CYP2D6. Therefore, drugs that are metabolized by CYP2D6 (eg. Metoprolol, PMID:12891223) should be used with caution in patients who also take celecoxib. The major routes of excretion for celecoxib are feces and urine.

PD: Celecoxib acts by inhibiting prostaglandin synthesis via inhibition of COX2 (PTGS2). Cox enzymes (PTGS1 and PTGS2) catalyze the committed step that leads to production of prostaglandins (PGH2) from arachidonic acid. PGH2s are then converted into active metabolites (prostaglandin E2 (PGE2), prostacyclin (PGI2), thromboxane (TXA2), prostaglandin D2 (PGD2), prostaglandin F2 (PGF2)) that mediate various physiological responses such as inflammation, fever, blood pressure regulation and clotting. PTGS1/COX-1 is constitutively expressed in many cell types, while PTGS2/COX-2 expression is negligible but can be induced by growth factors, cytokines and stress in many tissues. PTGS2 level is increased in inflammatory diseases such as arthritis and in cancer cells. Most of the NSAIDs inhibit both PTGS1 and PTGS2, Selected PTGS2/COX-2 inhibitors such as celecoxib (Celebrex) and rofecoxib (Vioxx) have been developed to treat information and provide pain relief. Celecoxib is the only NSAID approved to treat Familial Adenomatous Polyposis (FAP), a genetic condition that often leads to colorectal cancer. The use of celecoxib as a possible cancer treatment is currently being explored. The exact mechanisms for its anti-cancer activity are not clear, but they most likely involve both COX-dependent and COX-independent mechanisms. The anticarcinogenic mechanisms of celecoxib generally involve induction of apoptosis, cell cycle arrest, and regulation of angiogenesis. Inhibition of cell cycle progression mediated by celecoxib is observed along with increased expression of cell cycle inhibitors CDKN1A/p21, and CDKN1B/p27 and/or decreased expression of cyclins such CCNA1, CCNB1 and CCND1. Extensive degradation of CTNNB1 (beta-catenin, which promote cell proliferation) was also observed in celecoxib treated human colon cancer cells. Induction of apoptosis by celecoxib is associated with either activation of pro-apotosis molecules such as CASP3, CASP9 and DDIT3, and/or inhibition of anti-apoptosis molecules such as PDK1 and its downstream target AKT1. Celecoxib treatment also leads to decreased expression of VEGFA and inhibition of MMP9 in cancer cells suggesting a possible mechanism for inhibition of angiogenesis and decreased tumor growth.
AUTHORS:Li Gong
DATE POSTED:April 28, 2006
DATE LAST UPDATED:
pla2g2a pla2g4a nsaids ptgs2 ptgs1 ptgis akr1c3 pgds ptges tbxas1 cyp2c9 cyp3a4 cyp2d6 celecoxib vegfa mmp9 igfbp3 cdkn1a cdkn1B pparg ctnnb1 pdk1 akt1 casp9 bcar1 casp3 ddit3

The PharmGKB is financially supported by the NIH/ NIGMS and is managed at Stanford University (U01GM61374).
©2001-2010 PharmGKB.